

# John A Katzenellenbogen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7618919/publications.pdf>

Version: 2024-02-01

184  
papers

11,773  
citations

32410

55  
h-index

37326

100  
g-index

194  
all docs

194  
docs citations

194  
times ranked

11594  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of alcohol-enhanced Cu-mediated radiofluorination toward practical labeling. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2022, 65, 13-20.	0.5	3
2	Estradiol promotes cell survival and induces <i>Greb1</i> expression in granulosa cell tumors of the ovary through an ERI $\pm$ -dependent mechanism. <i>Journal of Pathology</i> , 2022, 256, 335-348.	2.1	9
3	FOXM1 regulates glycolysis and energy production in multiple myeloma. <i>Oncogene</i> , 2022, 41, 3899-3911.	2.6	16
4	The quest for improving the management of breast cancer by functional imaging: The discovery and development of $^{16}\alpha$ -[ $^{18}\text{F}$ ]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review. <i>Nuclear Medicine and Biology</i> , 2021, 92, 24-37.	0.3	38
5	Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 281-292.	1.1	25
6	Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis. <i>Brain Pathology</i> , 2021, 31, 312-332.	2.1	9
7	William C. Eckelman: An anchor of stability with a quiet voice that nurtured a new field. <i>Nuclear Medicine and Biology</i> , 2021, 92, 2-4.	0.3	0
8	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. <i>Nature Communications</i> , 2021, 12, 733.	5.8	33
9	Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1559-1570.	1.5	6
10	Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. <i>Biomedicines</i> , 2021, 9, 565.	1.4	18
11	Dual-mechanism estrogen receptor inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
12	Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets. <i>Nutrients</i> , 2021, 13, 3334.	1.7	5
13	Meet our advisors: An interview with John Katzenellenbogen. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 527-533.	0.5	0
14	Determination of molar activity of [ $^{18}\text{F}$ ]fluoride by HPLC via sulfonyl derivatization. <i>Applied Radiation and Isotopes</i> , 2021, 176, 109865.	0.7	1
15	Abstract P205: Novel 1,1-diarylethylene compounds degrade FOXM1 and selectively and potently reduce survival of high-grade serous ovarian cancer cells. , 2021, , .		0
16	Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer. <i>Cancers</i> , 2021, 13, 6282.	1.7	7
17	Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2677.	1.7	17
18	The tissue-specific effects of different $^{17}\beta$ -estradiol doses reveal the key sensitizing role of AF1 domain in ERI $\pm$ activity. <i>Molecular and Cellular Endocrinology</i> , 2020, 505, 110741.	1.6	10

#	ARTICLE	IF	CITATIONS
19	PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging. <i>Cancers</i> , 2020, 12, 2020.	1.7	19
20	A mutant form of ER $\alpha$ associated with estrogen insensitivity affects the coupling between ligand binding and coactivator recruitment. <i>Science Signaling</i> , 2020, 13, .	1.6	5
21	Long-Term Follow-Up and Treatment of a Female With Complete Estrogen Insensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1478-1488.	1.8	4
22	Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 297-307.	1.1	8
23	Differential Actions of Estrogen Receptor $\alpha$ and $\beta$ via Nongenomic Signaling in Human Prostate Stem and Progenitor Cells. <i>Endocrinology</i> , 2019, 160, 2692-2708.	1.4	23
24	Analogues of ER $\beta$ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 503.	1.6	17
25	Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor $\beta$ ligand-induced remyelination in a mouse model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2019, 130, 104501.	2.1	9
26	Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site. <i>Nature Communications</i> , 2019, 10, 1033.	5.8	22
27	Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. <i>Cancer Research</i> , 2019, 79, 2494-2510.	0.4	81
28	Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds. <i>Npj Breast Cancer</i> , 2019, 5, 45.	2.3	54
29	Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. <i>Nature Reviews Cancer</i> , 2018, 18, 377-388.	12.8	148
30	Respective role of membrane and nuclear estrogen receptor (ER) $\alpha$ in the mandible of growing mice: Implications for ER $\alpha$ modulation. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1520-1531.	3.1	9
31	Copper-mediated nucleophilic radiobromination of aryl boron precursors: Convenient preparation of a radiobrominated PARP-1 inhibitor. <i>Tetrahedron Letters</i> , 2018, 59, 1963-1967.	0.7	24
32	Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice. <i>Scientific Reports</i> , 2018, 8, 613.	1.6	53
33	Effects of Exposure to the Endocrine-Disrupting Chemical Bisphenol A During Critical Windows of Murine Pituitary Development. <i>Endocrinology</i> , 2018, 159, 119-131.	1.4	17
34	Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. <i>ACS Chemical Biology</i> , 2018, 13, 3374-3384.	1.6	8
35	Selective Nonnuclear Estrogen Receptor Activation Decreases Stroke Severity and Promotes Functional Recovery in Female Mice. <i>Endocrinology</i> , 2018, 159, 3848-3859.	1.4	25
36	Increase in chemokine CXCL1 by ER $\beta$ ligand treatment is a key mediator in promoting axon myelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6291-6296.	3.3	42

#	ARTICLE	IF	CITATIONS
37	Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal Î²-Glucuronidase Activity Without Impacting Overall Microbiome Community. <i>Scientific Reports</i> , 2018, 8, 8166.	1.6	40
38	New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 803-808.	1.3	47
39	Predominant Role of Nuclear Versus Membrane Estrogen Receptor Î± in Arterial Protection: Implications for Estrogen Receptor Î± Modulation in Cardiovascular Prevention/Safety. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	45
40	Estrogens and selective estrogen receptor modulators differentially antagonize Runx2 in ST2 mesenchymal progenitor cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 10-17.	1.2	6
41	Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. <i>Nuclear Medicine and Biology</i> , 2018, 66, 26-31.	0.3	29
42	Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins. <i>Science Signaling</i> , 2018, 11, .	1.6	17
43	Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 817-836.	2.6	30
44	Triaryl Pyrazole Tollâ€Like Receptor Signaling Inhibitors: Structureâ€Activity Relationships Governing Panâ€and Selective Signaling Inhibitors. <i>ChemMedChem</i> , 2018, 13, 2208-2216.	1.6	6
45	The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. <i>ELife</i> , 2018, 7, .	2.8	72
46	Estrogens and androgens inhibit association of RANKL with the preâ€osteoblast membrane through postâ€translational mechanisms. <i>Journal of Cellular Physiology</i> , 2017, 232, 3798-3807.	2.0	15
47	MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. <i>Hormones and Cancer</i> , 2017, 8, 69-77.	4.9	45
48	Evaluation of aromatic radiobromination by nucleophilic substitution using diaryliodonium salt precursors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 450-456.	0.5	15
49	Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. <i>Molecular Cell</i> , 2017, 65, 1122-1135.e5.	4.5	99
50	Exploring the Structural Compliancy versus Specificity of the Estrogen Receptor Using Isomeric Three-Dimensional Ligands. <i>ACS Chemical Biology</i> , 2017, 12, 494-503.	1.6	15
51	Systems Structural Biology Analysis of Ligand Effects on ERÎ± Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies. <i>Cell Chemical Biology</i> , 2017, 24, 35-45.	2.5	34
52	Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists. <i>Cancer Discovery</i> , 2017, 7, 277-287.	7.7	286
53	Selenophenes: Introducing a New Element into the Core of Nonâ€steroidal Estrogen Receptor Ligands. <i>ChemMedChem</i> , 2017, 12, 235-249.	1.6	19
54	Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. <i>Cancer Research</i> , 2017, 77, 5602-5613.	0.4	48

#	ARTICLE	IF	CITATIONS
55	17 $\beta$ -Estradiol Dysregulates Innate Immune Responses to <i>Pseudomonas aeruginosa</i> Respiratory Infection and Is Modulated by Estrogen Receptor Antagonism. <i>Infection and Immunity</i> , 2017, 85, .	1.0	50
56	Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6321-6336.	2.9	27
57	Full antagonism of the estrogen receptor without a prototypical ligand side chain. <i>Nature Chemical Biology</i> , 2017, 13, 111-118.	3.9	48
58	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. <i>ELife</i> , 2016, 5, .	2.8	212
59	Cyclic Ketoximes as Estrogen Receptor- $\beta$ Selective Agonists. <i>ChemMedChem</i> , 2016, 11, 1752-1761.	1.6	1
60	Dietary licorice root supplementation reduces diet-induced weight gain, lipid deposition, and hepatic steatosis in ovariectomized mice without stimulating reproductive tissues and mammary gland. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 369-380.	1.5	51
61	Predictive features of ligand-specific signaling through the estrogen receptor. <i>Molecular Systems Biology</i> , 2016, 12, 864.	3.2	41
62	Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues. <i>Science Signaling</i> , 2016, 9, ra53.	1.6	81
63	Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. <i>Cell Metabolism</i> , 2016, 23, 837-851.	7.2	130
64	Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. <i>Nature Chemical Biology</i> , 2016, 12, 795-801.	3.9	15
65	Estrogen receptor- $\alpha$ and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells. <i>Molecular and Cellular Endocrinology</i> , 2016, 437, 190-200.	1.6	22
66	Nonnuclear Estrogen Receptor Activation Improves Hepatic Steatosis in Female Mice. <i>Endocrinology</i> , 2016, 157, 3731-3741.	1.4	30
67	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 75S-80S.	2.8	43
68	Multiple Beneficial Roles of Repressor of Estrogen Receptor Activity (REA) in Suppressing the Progression of Endometriosis. <i>Endocrinology</i> , 2016, 157, 900-912.	1.4	15
69	Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 219-237.	2.9	50
70	Estrogen Receptor-Selective Agonists Modulate Learning in Female Rats in a Dose- and Task-Specific Manner. <i>Endocrinology</i> , 2016, 157, 292-303.	1.4	28
71	Licorice root components in dietary supplements are selective estrogen receptor modulators with a spectrum of estrogenic and anti-estrogenic activities. <i>Steroids</i> , 2016, 105, 42-49.	0.8	48
72	<i>Science Signaling</i> podcast for 24 May 2016: Designer estrogens. <i>Science Signaling</i> , 2016, 9, pc12.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Salicylketoximes That Target Glucose Transporter $\alpha$ 1 Restrict Energy Supply to Lung Cancer Cells. <i>ChemMedChem</i> , 2015, 10, 1892-1900.	1.6	19
74	Facile purification and click labeling with 2-[ $^{18}\text{F}$ ]fluoroethyl azide using solid phase extraction cartridges. <i>Tetrahedron Letters</i> , 2015, 56, 952-954.	0.7	17
75	Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. <i>Science Translational Medicine</i> , 2015, 7, 271ra9.	5.8	120
76	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor $\alpha$ positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
77	Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1063-1070.	3.2	31
78	Imidoyl dichlorides as new reagents for the rapid formation of 2-aminobenzimidazoles and related azoles. <i>Tetrahedron Letters</i> , 2015, 56, 6097-6099.	0.7	9
79	Preparation of $^{18}\text{F}$ -Fluorophenols from Nonaromatic Precursors: Mechanistic Considerations for Adaptation to Fluorine-18 Radiolabeling. <i>Organic Letters</i> , 2015, 17, 5540-5543.	2.4	20
80	Protective Hematopoietic Effect of Estrogens in a Mouse Model of Thrombosis: Respective Roles of Nuclear Versus Membrane Estrogen Receptor $\alpha$ . <i>Endocrinology</i> , 2015, 156, 4293-4301.	1.4	8
81	Fluorescent Nanoconjugate Derivatives with Enhanced Photostability for Single Molecule Imaging. <i>Analytical Chemistry</i> , 2015, 87, 11048-11057.	3.2	14
82	Neural-Network Scoring Functions Identify Structurally Novel Estrogen-Receptor Ligands. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1953-1961.	2.5	31
83	Estrogen Receptor Alpha/Co-activator Interaction Assay: TR-FRET. <i>Methods in Molecular Biology</i> , 2015, 1278, 545-553.	0.4	5
84	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. <i>ELife</i> , 2014, 3, e02057.	2.8	113
85	Optimization of the preparation of fluorine $^{18}$ -labeled steroid receptor ligands 16 $\alpha$ - $^{18}\text{F}$ fluoroestradiol (FES), [ $^{18}\text{F}$ ]fluoro furanyl norprogesterone (FFNP), and 16 $\beta$ - $^{18}\text{F}$ fluoro $\alpha$ 5 $\alpha$ -dihydrotestosterone (FDHT) as radiopharmaceuticals. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 371-377.	0.5	32
86	Multiple functional therapeutic effects of the estrogen receptor $\beta$ agonist indazole-Cl in a mouse model of multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18061-18066.	3.3	77
87	The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor $\beta$ modulation, uncoupling nuclear and membrane activation. <i>EMBO Molecular Medicine</i> , 2014, 6, 1328-1346.	3.3	96
88	Synthesis and receptor binding in trans-CD ring-fused A-CD estrogens: Comparison with the cis-fused isomers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3841-3844.	1.0	1
89	Estrogen receptors alpha ( $\text{ER}\alpha$ ) and beta ( $\text{ER}\beta$ ): Subtype-selective ligands and clinical potential. <i>Steroids</i> , 2014, 90, 13-29.	0.8	490
90	Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling. <i>Cancer Research</i> , 2014, 74, 3959-3970.	0.4	32

#	ARTICLE	IF	CITATIONS
91	Integrative genomics of gene and metabolic regulation by estrogen receptors $\hat{1}$ and $\hat{2}$ , and their coregulators. <i>Molecular Systems Biology</i> , 2013, 9, 676.	3.2	81
92	Ligand-binding dynamics rewire cellular signaling via estrogen receptor- $\hat{1}$ . <i>Nature Chemical Biology</i> , 2013, 9, 326-332.	3.9	53
93	Synthesis and biological evaluation of RGD peptides with the $^{99m}\text{Tc}/^{188}\text{Re}$ chelated iminodiacetate core: highly enhanced uptake and excretion kinetics of theranostics against tumor angiogenesis. <i>RSC Advances</i> , 2013, 3, 782-792.	1.7	26
94	Mechanisms enforcing the estrogen receptor $\hat{2}$ selectivity of botanical estrogens. <i>FASEB Journal</i> , 2013, 27, 4406-4418.	0.2	92
95	Designer antiandrogens join the race against drug resistance. <i>ELife</i> , 2013, 2, e00692.	2.8	6
96	Assessment of Progesterone Receptors in Breast Carcinoma by PET with $^{21}\text{-}^{18}\text{F}$ -Fluoro- $^{16}\hat{1}$ , $^{17}\hat{1}$ -[ <i>(R)</i> -( $^{1}\hat{2}$ -furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370.	2.8	71
97	Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1119-1126.	2.8	63
98	Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 8692.	1.5	30
99	Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2324-2341.	2.9	36
100	Development of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands. <i>ChemMedChem</i> , 2012, 7, 1094-1100.	1.6	27
101	The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: Addressing the "Core Issue" in the Design of Estrogen Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5271-5282.	2.9	76
102	Reduction of stimulated sodium iodide symporter expression by estrogen receptor ligands in breast cancer cells. <i>Nuclear Medicine and Biology</i> , 2011, 38, 287-294.	0.3	4
103	Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) <b>RAD140</b> . <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 124-129.	1.3	48
104	Exploration of Dimensions of Estrogen Potency. <i>Journal of Biological Chemistry</i> , 2011, 286, 12971-12982.	1.6	76
105	Coupling of receptor conformation and ligand orientation determine graded activity. <i>Nature Chemical Biology</i> , 2010, 6, 837-843.	3.9	121
106	Development of [ $^{18}\text{F}$ ]Fluorine-Substituted Tanaproget as a Progesterone Receptor Imaging Agent for Positron Emission Tomography. <i>Bioconjugate Chemistry</i> , 2010, 21, 1096-1104.	1.8	42
107	Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3320-3329.	2.9	49
108	PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 509-517.	1.1	189

#	ARTICLE	IF	CITATIONS
109	Analogues of methyl-piperidinopyrazole (MPP): Antiestrogens with estrogen receptor $\beta$ selective activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 108-110.	1.0	46
110	NF $\kappa$ B selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. <i>Nature Chemical Biology</i> , 2008, 4, 241-247.	3.9	149
111	Evaluation of a bromine-76-labeled progestin 16 $\beta$ ,17 $\beta$ -dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. <i>Nuclear Medicine and Biology</i> , 2008, 35, 655-663.	0.3	16
112	Synthesis of 7 $\beta$ -(Fluoromethyl)dihydrotestosterone and 7 $\beta$ -(Fluoromethyl)nortestosterone, Structurally Paired Androgens Designed To Probe the Role of Sex Hormone Binding Globulin in Imaging Androgen Receptors in Prostate Tumors by Positron Emission Tomography. <i>Journal of Organic Chemistry</i> , 2007, 72, 5546-5554.	1.7	23
113	Fluorine-Substituted Cyclofenil Derivatives as Estrogen Receptor Ligands: A Synthesis and Structure-Affinity Relationship Study of Potential Positron Emission Tomography Agents for Imaging Estrogen Receptors in Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2496-2511.	2.9	45
114	Kinase-Specific Phosphorylation of the Estrogen Receptor Changes Receptor Interactions with Ligand, Deoxyribonucleic Acid, and Coregulators Associated with Alterations in Estrogen and Tamoxifen Activity. <i>Molecular Endocrinology</i> , 2006, 20, 3120-3132.	3.7	166
115	Receptor Imaging of Tumors (Non-Peptide). , 2005, , 715-750.		3
116	Designing Effective Hybrid Toxins. <i>Chemistry and Biology</i> , 2005, 12, 719-721.	6.2	2
117	A Proteomic Microarray Approach for Exploring Ligand-initiated Nuclear Hormone Receptor Pharmacology, Receptor Selectivity, and Heterodimer Functionality. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 267-277.	2.5	35
118	Coactivator Proteins as Determinants of Estrogen Receptor Structure and Function: Spectroscopic Evidence for a Novel Coactivator-Stabilized Receptor Conformation. <i>Molecular Endocrinology</i> , 2005, 19, 1516-1528.	3.7	45
119	Synthesis of an Estrogen Receptor $\beta$ -Selective Radioligand: A 5-[18F]Fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and Comparison of in Vivo Distribution with 16 $\beta$ -[18F]Fluoro-17 $\beta$ -estradiol. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6366-6378.	2.9	74
120	Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: A New Class of Estrogen Antagonists of Unusual Structure. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7261-7274.	2.9	64
121	Ligand-Induced Changes in Estrogen Receptor Conformation As Measured by Site-Directed Spin Labeling. <i>Biochemistry</i> , 2004, 43, 1891-1907.	1.2	31
122	Bridged Bicyclic Cores Containing a 1,1-Diarylethylene Motif Are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1589-1602.	2.9	89
123	Estrogen Receptor Dimerization: Ligand Binding Regulates Dimer Affinity and Dimer Dissociation Rate. <i>Molecular Endocrinology</i> , 2002, 16, 2706-2719.	3.7	145
124	Antagonists Selective for Estrogen Receptor $\beta$ . <i>Endocrinology</i> , 2002, 143, 941-947.	1.4	231
125	A convenient method for the preparation of highly substituted pyrimidines: Synthesis of tri- and tetra-substituted pyrimidines from 1,3-dicarbonyl compounds and <i>N,N,N</i> -tris(trimethylsilyl)amidines. <i>Journal of Heterocyclic Chemistry</i> , 2002, 39, 1101-1104.	1.4	25
126	Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. <i>Nature Structural Biology</i> , 2002, 9, 359-64.	9.7	188



#	ARTICLE	IF	CITATIONS
127	Estrogen Receptor- $\beta$ Potency-Selective Ligands: Structure-Activity Relationship Studies of Diarylpropionitriles and Their Acetylene and Polar Analogues. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4230-4251.	2.9	648
128	Comparison of animal models for the evaluation of radiolabeled androgens. <i>Nuclear Medicine and Biology</i> , 2001, 28, 613-626.	0.3	19
129	Activation of estrogen receptor $\beta$ is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. <i>FEBS Letters</i> , 2001, 502, 103-108.	1.3	97
130	Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2797-2803.	0.8	377
131	Triarylpyrazoles with basic side chains. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 151-161.	1.4	86
132	Estrogen pyrazoles: defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 141-150.	1.4	96
133	Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 448-462.	1.2	75
134	Halogen-substituted triarylpyrazoles: Potential estrogen receptor $\alpha$ selective radiopharmaceuticals. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S342.	0.5	0
135	Probing Conformational Changes in the Estrogen Receptor: Evidence for a Partially Unfolded Intermediate Facilitating Ligand Binding and Release. <i>Molecular Endocrinology</i> , 2001, 15, 421-428.	3.7	60
136	Pyrazole Ligands: Structure-Affinity/Activity Relationships and Estrogen Receptor- $\beta$ -Selective Agonists. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4934-4947.	2.9	724
137	Preparation of Hexahydrobenzo[f]isoquinolines Using a Vinylogous Pictet-Spengler Cyclization. <i>Organic Letters</i> , 2000, 2, 3635-3638.	2.4	24
138	Solid-Phase Synthesis of Tetrasubstituted Pyrazoles, Novel Ligands for the Estrogen Receptor. <i>ACS Combinatorial Science</i> , 2000, 2, 318-329.	3.3	80
139	Regioselective Synthesis of 1,3,5-Triaryl-4-alkylpyrazoles: Novel Ligands for the Estrogen Receptor. <i>Organic Letters</i> , 2000, 2, 2833-2836.	2.4	180
140	Coactivator Peptides Have a Differential Stabilizing Effect on the Binding of Estrogens and Antiestrogens with the Estrogen Receptor. <i>Molecular Endocrinology</i> , 1999, 13, 1912-1923.	3.7	123
141	Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor- $\beta$ or Estrogen Receptor- $\alpha$ . <i>Endocrinology</i> , 1999, 140, 800-804.	1.4	305
142	Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 51-56.	3.3	254
143	A Polymer-Supported Phosphazene as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes. <i>Angewandte Chemie - International Edition</i> , 1999, 38, 1617-1620.	7.2	24
144	Comparative breast tumor imaging and comparative in vitro metabolism of $^{16}\beta$ -[ $^{18}\text{F}$ ]Fluoroestradiol- $\beta$ and $^{16}\alpha$ -[ $^{18}\text{F}$ ]fluoromoxestrol in isolated hepatocytes. <i>Nuclear Medicine and Biology</i> , 1999, 26, 123-130.	0.3	47

#	ARTICLE	IF	CITATIONS
145	Integrated $\text{Os}^3+$ Oxorhenium(V) Complexes as Estrogen Mimics. <i>Bioconjugate Chemistry</i> , 1999, 10, 119-129.	1.8	29
146	Three-Component Synthesis of Substituted $\eta^5$ -Cyclopentadienyltricarbonylrhenium Complexes: A Scope, Limitations, and Mechanistic Interpretations. <i>Organometallics</i> , 1999, 18, 2519-2530.	1.1	30
147	Estrogen Receptor Subtype-Selective Ligands: Asymmetric Synthesis and Biological Evaluation of cis- and trans-5,11-Dialkyl-5,6,11,12-tetrahydrochrysenes. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2456-2468.	2.9	150
148	Preparation of Cyclopentadienyltricarbonylrhenium Complexes Using a Double Ligand-Transfer Reaction. <i>Organometallics</i> , 1998, 17, 2009-2017.	1.1	83
149	Synthesis of a Tetradentate Oxorhenium(V) Complex Mimic of a Steroidal Estrogen. <i>Journal of Organic Chemistry</i> , 1997, 62, 6290-6297.	1.7	41
150	Synthesis and Spectroscopic Characterization of Two Azatetrahydrochrysenes as Potential Fluorescent Ligands for the Estrogen Receptor. <i>Journal of Organic Chemistry</i> , 1997, 62, 7650-7657.	1.7	10
151	1-Aryl-2-pyridyl-3,4-dihydronaphthalenes: Photofluorogenic Ligands for the Estrogen Receptor. <i>Journal of Organic Chemistry</i> , 1997, 62, 1043-1057.	1.7	22
152	Altered Ligand Binding Properties and Enhanced Stability of a Constitutively Active Estrogen Receptor: Evidence That an Open Pocket Conformation Is Required for Ligand Interaction. <i>Biochemistry</i> , 1997, 36, 14897-14905.	1.2	203
153	Trifluoromethyl-Substituted Imidazolines: Novel Precursors of Trifluoromethyl Ketones Amenable to Peptide Synthesis. <i>Journal of the American Chemical Society</i> , 1996, 118, 8485-8486.	6.6	28
154	Haloenol lactones as inactivators and substrates of aldehyde dehydrogenase. <i>The Protein Journal</i> , 1996, 15, 639-648.	1.1	3
155	Fluorine-18-labeled progestin 16.alpha.,17.alpha.-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 328-337.	2.9	65
156	Analysis of the Structural Core of the Human Estrogen Receptor Ligand Binding Domain by Selective Proteolysis/Mass Spectrometric Analysis. <i>Biochemistry</i> , 1995, 34, 12605-12615.	1.2	72
157	Oxohexestrol derivatives labeled with fluorine-18. Synthesis, receptor binding and in vivo distribution of two non-steroidal estrogens as potential breast tumor imaging agents. <i>Nuclear Medicine and Biology</i> , 1994, 21, 25-39.	0.3	14
158	Synthesis and NMR spectrum of $[^{13}\text{C}^{18}]$ -meso-hexestrol, a fully carbon-13 substituted ligand for NMR studies of the estrogen receptor. <i>Magnetic Resonance in Chemistry</i> , 1993, 31, 977-986.	1.1	1
159	CHARACTERIZATION OF THE SPECTROSCOPIC PROPERTIES OF A TETRAHYDROCHRYSENE SYSTEM CONTAINING A RIGIDIFIED HYDROXYNITROSTILBENE CHROMOPHORE: AN INHERENTLY FLUORESCENT LIGAND DESIGNED FOR THE ESTROGEN RECEPTOR. <i>Photochemistry and Photobiology</i> , 1993, 57, 616-628.	1.3	19
160	THE EFFECT OF ACCEPTOR GROUP VARIATION ON THE SOLVATOCHROMISM OF DONOR-ACCEPTOR FLUOROPHORES. <i>Photochemistry and Photobiology</i> , 1993, 58, 785-794.	1.3	11
161	$^{16}\text{O}$ - $^{18}\text{F}$ fluoromoxestrol: A potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. <i>Life Sciences</i> , 1993, 53, 811-819.	2.0	32
162	Fluorine-18 labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 1120-1127.	2.9	48

#	ARTICLE	IF	CITATIONS
163	Titration of the in vivo uptake of $16\beta$ -[ $^{18}\text{F}$ ]fluoroestradiol by target tissues in the rat: Competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. <i>Nuclear Medicine and Biology</i> , 1993, 20, 735-745.	0.3	49
164	Preparation and evaluation of 17-ethynyl-substituted $16\beta$ -[ $^{18}\text{F}$ ]fluoroestradiols: Selective receptor-based PET imaging agents. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 363-374.	0.3	23
165	Fluorine-substituted corticosteroids: Synthesis and evaluation as potential receptor-based imaging agents for positron emission tomography of the brain. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 461-480.	0.3	13
166	Donor-acceptor tetrahydrochrysenes, inherently fluorescent, high-affinity ligands for the estrogen receptor: binding and fluorescence characteristics and fluorometric assay of receptor. <i>Biochemistry</i> , 1992, 31, 11536-11545.	1.2	52
167	11.β-Methoxy-, 11.β-ethyl, and 17.α-ethynyl-substituted 16.α-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 3143-3155.	2.9	128
168	Binding of $16\beta$ -[ $^{18}\text{F}$ ]Fluoro- $17\beta$ -estradiol to alphafetoprotein in Sprague-Dawley female rats affects blood levels. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1990, 17, 769-773.	0.3	5
169	HYDROXYSTILBAZOLES AND HYDROXYAZAPHENANTHRENS: PHOTOCYCLIZATION AND FLUORESCENCE STUDIES. <i>Photochemistry and Photobiology</i> , 1988, 47, 503-516.	1.3	23
170	$11\beta$ -Chloromethyl-[ $^3\text{H}$ ]estradiol- $17\beta$ : A very high affinity, reversible ligand for the estrogen receptor. <i>The Journal of Steroid Biochemistry</i> , 1987, 28, 361-370.	1.3	36
171	Characterization of the uptake of $16\beta$ -([ $^{18}\text{F}$ ]fluoro)- $17\beta$ -estradiol in DMBA-induced mammary tumors. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1987, 14, 15-25.	0.3	39
172	NCA $16\beta$ -[ $^{18}\text{F}$ ]fluoroestradiol- $17\beta$ : The effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1986, 37, 217-221.	0.5	60
173	Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomers. <i>The Journal of Steroid Biochemistry</i> , 1985, 22, 589-596.	1.3	85
174	Synthesis of 16-fluoroestrogens by unusually facile fluoride ion displacement reactions: prospects for the preparation of fluorine-18 labeled estrogens. <i>Journal of Organic Chemistry</i> , 1984, 49, 4900-4905.	1.7	73
175	( $2\alpha$ -, $3\alpha$ -)-1-[ $^{18}\text{F}$ ]fluoro-2, 3-bis (4-hydroxyphenyl) pentane ([ $^{18}\text{F}$ ]fluoronorhexestrol), A positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo. <i>Life Sciences</i> , 1983, 33, 1933-1938.	2.0	26
176	Factors affecting the target site uptake selectivity of estrogen radiopharmaceuticals: Serum binding and endogenous estrogens. <i>The Journal of Steroid Biochemistry</i> , 1983, 18, 635-641.	1.3	40
177	Methodology for the synthesis and specific activity determination of $16\beta$ -[ $^{77}\text{Br}$ ]-Bromoestradiol- $17\beta$ and $16\beta$ -[ $^{77}\text{Br}$ ]-11 $\beta$ -methoxyestradiol- $17\beta$ , Two estrogen receptor-binding radiopharmaceuticals. <i>The International Journal of Applied Radiation and Isotopes</i> , 1982, 33, 545-551.	0.7	60
178	Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens Cl628 and U23,469*. <i>Endocrinology</i> , 1981, 108, 164-172.	1.4	39
179	Estrogen receptor-based imaging agents. 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens. <i>Journal of Medicinal Chemistry</i> , 1980, 23, 994-1002.	2.9	57
180	Iodohexestrols. I. Synthesis and photoreactivity of iodinated hexestrol derivatives. <i>Biochemistry</i> , 1975, 14, 1736-1741.	1.2	13

#	ARTICLE	IF	CITATIONS
181	Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo. <i>Biochemistry</i> , 1975, 14, 1742-1750.	1.2	41
182	An Efficient, General Synthesis of Alkylsulfinyltoluidides. <i>Synthetic Communications</i> , 1974, 4, 137-141.	1.1	6
183	Photoaffinity labels for estrogen binding proteins of rat uterus. <i>Biochemistry</i> , 1973, 12, 4085-4092.	1.2	245
184	Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor- $\alpha$ or Estrogen Receptor- $\beta$ . , 0, .		107